NDLI: Bon usage d'apixaban: que retenir pour la pratique.

Please wait, while we are loading the content...

Recommandations de bonne pratique concernant la sécurité et l'environnement en médecine vasculaire, notamment pour le traitement des varices, proposées par la Société française de médecine vasculaire.

Un anévrisme de l'artère carotide interne d'origine dysplasique.

Un anévrysme de l'aorte abdominale révélant une maladie de Behçet.

Year: 2014 Volume: 39 Issue: 4

Year: 2014 Volume: 39 Issue: 3

Year: 2014 Volume: 39 Issue: 1

Year: 2013 Volume: 38

Year: 2012 Volume: 37

Year: 2011 Volume: 36

Year: 2010 Volume: 35

Year: 2009 Volume: 34

Year: 2008 Volume: 33

Year: 2008 Volume: 33 Spec No 2

Bon usage d'apixaban: que retenir pour la pratique.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Albaladejo, P. Deplanque, D. Fossati, F. Mahagne, M. H. Mismetti, P. Nguyen, P. Roy, P. Touze, E. Mourad, J-J
Spatial Coverage	France
Description	Country affiliation: France Author Affiliation: Albaladejo P ( Service d'anesthésie-réanimation, CHU de Grenoble, BP 217, 38043 Grenoble cedex 09, France.); Deplanque D ( Laboratoire de pharmacologie, faculté de médecine, CHR de Lille, 1, place de Verdun, 59045 Lille, France.); Fossati F ( 12, rue de Condé, 59110 La Madeleine, France.); Mahagne MH ( Unité neurovasculaire, hôpital Saint-Roch, CHU de Nice, 5, rue Pierre-Devoluy, BP 319, 06006 Nice cedex 1, France.); Mismetti P ( Service médecine et thérapeutique, hôpital Bellevue, CHU de Saint-Étienne, 42055 Saint-Étienne cedex 2, France.); Nguyen P ( Laboratoire central d'hématologie, hôpital Robert-Debré, CHU de Reims, avenue du Général-Koenig, 51092 Reims cedex, France.); Roy P ( Accueil et traitement urgences, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France.); Touze E ( Service de neurologie, hôpital Sainte-Anne, 1, rue Cabanis, 75014 Paris, France.); Mourad JJ ( Unité médecine interne, HTA, hôpital Avicenne-AP-HP, 125, rue de Stalingrad, 93009 Bobigny cedex, France. Electronic address: jean-jacques.mourad@avc.aphp.fr.)
Abstract	Apixaban is a direct inhibitor of coagulation factor Xa. Superior efficacy over aspirin and antivitamin K has been shown in the prevention of stroke and systemic embolism during non-valvular atrial fibrillation with a more favorable safety profile, even though the risk of hemorrhage cannot be ignored, considering its mechanism of action. The recommended dose is 5mg twice daily which can be reduced to 2.5mg depending on the individual risk. Apixaban is also indicated for the treatment of venous thromboembolism but reimbursement has not yet been accepted in France for this indication. As with all direct oral anticoagulants, no routine biological monitoring is required, nevertheless their use may have an impact on all coagulation tests, eventually hampering interpretation. In particular clinical circumstances where a measure of anticoagulant efficacy is deemed necessary, specific assay of anti-Xa activity is appropriate, the result being expressed as concentration of the anticoagulant used. It is therefore necessary to state the name of the medicine for which the assay is requested. With these new anticoagulants, management of hemorrhagic events can be more difficult due to the lack of a specific antidote. Pro-hemostatic substances have exhibited efficacy in animal models but results are still insufficiently documented in clinical practice. Local or locoregional hemostasis measurements, when possible, are an essential factor in the treatment of hemorrhagic events.
File Format	HTM / HTML
ISSN	03980499
Issue Number	6
Volume Number	39
e-ISSN	22148116
Journal	Journal des Maladies Vasculaires
Language	French
Publisher	Elsevier
Publisher Date	2014-12-01
Publisher Place	France
Access Restriction	Subscribed
Subject Keyword	Discipline Vascular Diseases Cardiovascular Diseases Drug Therapy Factor Xa Inhibitors Therapeutic Use Pyrazoles Pyridones Animals Anticoagulants Atrial Fibrillation Complications Prevention & Control Surgery Drug Interactions Embolism Administration & Dosage Adverse Effects France Hemorrhage Chemically Induced Humans Stroke Venous Thromboembolism English Abstract Journal Article
Content Type	Text
Resource Type	Article
Subject	Cardiology and Cardiovascular Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in